
CASE DISCUSSION
Case Discussion on Neonatal Jaundice
Presented from India by Dr. Pandu Chouhan0
Likes
3167
Views
127
Shares
95
Bookmarks
0
Credit Points
0
Learning Hours
0
CPD/CME Points
0
Courses Completed
Case Description
Neonatal jaundice, characterized by yellowing of a newborn's skin and eyes, is a common occurrence in the first days of life. It occurs due to the accumulation of bilirubin, a yellow pigment produced from the breakdown of red blood cells. In most cases, neonatal jaundice is physiological, resulting...
Case Summary
- Neonatal jaundice, or hyperbilirubinemia, is a common condition characterized by elevated bilirubin levels in newborns, resulting in yellowing of the skin, mucous membranes, and sclera. It's defined as a total serum bilirubin level exceeding the 95th percentile for age. Jaundice can stem from hepatic, extra-hepatic (obstructive), or hemolytic causes, but the focus here is on disorders of bilirubin metabolism where liver diseases are absent.
Speaker Profile

Dr. Pandu Chouhan
Consultant Pediatric Gastroenterology, KIMS Hospital, HyderabadDr. Pandu Chouhan, an accomplished pediatric gastroenterologist, completed his MBBS and internship at Osmania Medical College, Hyderabad, and earned his MD in Pediatrics from AIIMS, New Delhi (2015–2018). He also completed a Fellowship in Gastrointestinal Endoscopy (2021, WLH, New Delhi) and gained 18 months of specialized experience in Pediatric Gastroenterology at AIIMS, where he served as a Senior Resident (2018–2021). With over six years of experience, including a tenure as Assistant Professor at Rajshree Medical Research Institute (2021–2022), Dr. Chouhan has performed over 100 upper GI endoscopies, 50 EVLs, 30 liver biopsies in children, and multiple sigmoidoscopies, proctoscopies, capsule endoscopies, and therapeutic paracentesis procedures.
Disclosures
Assimilate requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships for anyone with the ability to control the content of this educational activity have been reviewed and mitigated. Others involved in the planning of this activity have no relevant financial relationships.